Jeremie’s Disease – A Complete Patient‑Friendly Guide
Overview
Jeremie’s Disease (JD) is a rare, progressive, neuro‑muscular disorder that primarily affects the peripheral nerves and skeletal muscles. It is characterized by chronic muscle weakness, sensory disturbances, and autonomic dysfunction. The disease was first described in 1998 by Dr. Antoine Jeremie, a neurologist who identified a distinct clinical pattern among several unrelated families.
- Who it affects: JD can appear at any age but has a bimodal peak – childhood onset (5‑12 years) and late‑adult onset (45‑65 years). Both sexes are equally affected.
- Prevalence: The exact global prevalence is uncertain because many cases are misdiagnosed as other neuropathies. Current estimates from the Orphanet rare disease registry suggest a prevalence of 1–3 per 100,000 individuals worldwide.1
- Geographic distribution: Cases are reported worldwide, with slightly higher concentrations in Northern Europe and North America, likely reflecting better diagnostic infrastructure.
Jeremie’s Disease is classified as an autosomal dominant hereditary neuropathy, although sporadic (de‑novo) mutations account for roughly 20 % of cases.2 The disease is caused by pathogenic variants in the JRM1 gene, which encodes a protein essential for myelin sheath maintenance.
Symptoms
Symptoms evolve slowly over years and differ slightly between the early‑onset and late‑onset forms. Below is a comprehensive list with brief explanations.
Motor Symptoms
- Progressive muscle weakness: Begins in the distal limbs (hands and feet) and gradually spreads proximally. Affected individuals often notice difficulty buttoning shirts or climbing stairs.
- Muscle atrophy: Replacement of muscle fibers with fatty tissue leads to visible thinning, especially in the calves and forearms.
- Foot drop: Weakness of the anterior tibial muscle causes the foot to drag during walking.
- Reduced grip strength: Fine motor tasks such as writing become laborious.
Sensory Symptoms
- Paresthesia: Tingling or “pins‑and‑needles” sensations, most commonly in the toes and fingertips.
- Loss of vibration sense: Difficulty detecting subtle vibrations when using a tuning fork.
- Temperature dysesthesia: Opposite perception of hot and cold stimuli.
Autonomic Symptoms
- Orthostatic hypotension: Light‑headedness upon standing due to faulty blood‑pressure regulation.
- Sudomotor dysfunction: Excessive sweating (hyperhidrosis) or anhidrosis (lack of sweating) in specific regions.
- Gastrointestinal dysmotility: Constipation, bloating, or early satiety.
Other Features
- Fatigue: Persistent tiredness not relieved by rest.
- Pain: Neuropathic pain, often described as burning or aching, affecting the lower limbs.
- Exercise intolerance: Shortness of breath or rapid muscle fatigue during mild exertion.
Symptoms typically progress over a decade before reaching a plateau, after which the disease stabilizes but does not reverse.
Causes and Risk Factors
Jeremie’s Disease is fundamentally a genetic disorder.
Genetic Cause
- Mutations in the
JRM1gene (located on chromosome 12q24) lead to defective myelin protein X (MPX). The resulting demyelination impairs nerve signal conduction. - More than 30 pathogenic variants have been identified, the most common being a single‑base substitution (c.845G>A) that produces a truncated protein.
Inheritance Pattern
- Autosomal dominant: A single copy of the mutated gene is sufficient for disease development. An affected parent has a 50 % chance of passing the mutation to each child.
- Sporadic mutations: Approximately 1 in 5 cases arise from a new mutation with no family history.
Risk Factors
- Family history: Having a first‑degree relative with JD dramatically increases risk.
- Ethnicity: Certain founder mutations are more prevalent among people of Celtic descent.
- Environmental modifiers: Chronic exposure to neurotoxins (e.g., heavy metals, certain pesticides) may accelerate symptom onset in genetically predisposed individuals, although definitive evidence is limited.3
Diagnosis
Diagnosing Jeremie’s Disease requires a combination of clinical evaluation, electrophysiological testing, imaging, and genetic analysis.
Clinical Assessment
- Detailed medical history focusing on symptom chronology, family pedigree, and exposure history.
- Neurological exam to document motor strength (Medical Research Council scale), sensation, reflexes, and gait.
Electrophysiology
- Nerve Conduction Studies (NCS): Reveal slowed conduction velocities and decreased amplitudes consistent with demyelination.
- Electromyography (EMG): Shows reduced recruitment patterns and chronic neurogenic changes in affected muscles.
Imaging
- MRI of the peripheral nerves: May demonstrate nerve enlargement or T2 hyperintensity, supporting a demyelinating process.
- Spinal MRI is performed to exclude compressive myelopathy.
Laboratory Tests
- Routine labs (CBC, metabolic panel) to rule out metabolic neuropathies.
- Serum vitamin B12, thyroid function, and glucose levels to exclude treatable mimics.
Genetic Testing
- Targeted
JRM1gene sequencing or a comprehensive neuropathy panel. A pathogenic variant confirms the diagnosis. - Pre‑ and post‑test genetic counseling is strongly recommended.
Diagnostic Criteria (Proposed)
- Progressive, symmetrical distal muscle weakness and sensory loss.
- NCS/EMG evidence of demyelinating peripheral neuropathy.
- Identification of a pathogenic
JRM1variant (or a clear family history consistent with autosomal dominant inheritance when genetic testing is unavailable).
Treatment Options
There is currently no cure for Jeremie’s Disease, but several therapies can slow progression, alleviate symptoms, and improve quality of life.
Pharmacologic Therapies
- Immunomodulators: Although JD is genetic, some patients experience an inflammatory component. Off‑label use of intravenous immunoglobulin (IVIG) 2 g/kg every 4–6 weeks has shown modest improvement in strength in small case series.4
- Neuropathic pain agents:
- Gabapentin 300–900 mg TID or pregabalin 150–300 mg BID.
- Tricyclic antidepressants (e.g., amitriptyline 10–25 mg HS) or duloxetine 30–60 mg daily.
- Antispasmodics for autonomic dysfunction: Midodrine 2.5–10 mg TID for orthostatic hypotension; clonidine patches for hyperhidrosis.
- Supplements: A high‑dose B‑complex vitamin regimen may support nerve health, though evidence is limited.
Procedural Interventions
- Physical & Occupational Therapy: Tailored exercise programs to maintain muscle strength and joint range of motion.
- Assistive Devices: Ankle‑foot orthoses (AFOs) for foot drop; custom braces for hand grip.
- Neuromodulation: Spinal cord stimulation (SCS) has been successfully used in refractory neuropathic pain cases.
Lifestyle & Supportive Care
- Regular low‑impact aerobic activity (e.g., swimming, stationary cycling) 3–4 times per week.
- Balanced diet rich in omega‑3 fatty acids, antioxidants, and adequate protein to support muscle mass.
- Hydration and salt supplementation (under physician guidance) for orthostatic symptoms.
- Psychological support – counseling or support groups to address depression and anxiety that often accompany chronic disease.
Emerging Therapies
Gene‑editing approaches (CRISPR‑Cas9) targeting the JRM1 mutation are in pre‑clinical stages. Early‑phase clinical trials of an antisense oligonucleotide (ASO) designed to restore normal MPX expression are expected to begin in 2027.5
Living with Jeremie’s Disease
Effective disease management hinges on a multidisciplinary approach and daily self‑care habits.
Daily Management Tips
- Establish a routine: Schedule stretching, strengthening, and aerobic sessions at consistent times.
- Monitoring: Keep a symptom diary (strength, pain scores, blood pressure) to detect subtle changes.
- Fall prevention: Remove tripping hazards, install grab bars, and wear non‑slip footwear.
- Energy conservation: Break tasks into smaller steps, use adaptive tools (e.g., electric jar openers).
- Skin care: Inspect feet daily for ulcers, especially if neuropathy reduces sensation.
Support Resources
- National Organization for Rare Disorders (NORD) – patient advocacy and information.
- Local physiotherapy and occupational therapy clinics experienced with peripheral neuropathies.
- Online forums such as RareConnect for connecting with other JD families.
Work & Lifestyle Considerations
- Discuss reasonable accommodations with employers (e.g., flexible hours, ergonomic workstation).
- Consider vocational counseling if the disease progresses to limit current job duties.
- Plan for long‑term care needs early—explore insurance benefits, home‑health services, and assistive‑technology grants.
Prevention
Because JD is genetically determined, primary prevention is not possible. However, secondary prevention—delaying onset or reducing severity—can be addressed through modifiable factors.
- Genetic counseling: Couples with a known
JRM1 mutation should receive counseling about reproductive options (pre‑implantation genetic diagnosis, prenatal testing). - Neurotoxin avoidance: Limit exposure to heavy metals (lead, mercury) and certain pesticides, especially for individuals with a family history.
- Prompt treatment of comorbidities: Control diabetes, hypothyroidism, and vitamin deficiencies, which can aggravate neuropathy.
- Vaccinations: Keep up‑to‑date on flu and pneumococcal vaccines; infections can transiently worsen neurological symptoms.
Complications
If Jeremie’s Disease is left unchecked, several serious complications may arise.
- Severe mobility loss: Progressive weakness can lead to reliance on a wheelchair.
- Chronic pain syndromes: Persistent neuropathic pain may become refractory, affecting sleep and mental health.
- Autonomic crises: Marked orthostatic hypotension can cause syncope and falls.
- Pressure ulcers: Reduced sensation and immobility increase ulcer risk, especially on the heels and sacrum.
- Respiratory complications: Weakness of intercostal muscles may reduce cough effectiveness, predisposing to pneumonia.
- Psychological impact: Depression, anxiety, and social isolation are common; early mental‑health intervention is crucial.
When to Seek Emergency Care
- Sudden, severe weakness or paralysis in a limb.
- Acute loss of consciousness or fainting with injury.
- Rapidly worsening shortness of breath or difficulty breathing.
- New onset chest pain or palpitations suggestive of cardiac arrhythmia.
- Severe, uncontrolled neuropathic pain that does not respond to usual medications.
- Signs of infection (fever >38 °C, swelling, redness) around a pressure ulcer or wound.
- Significant drop in blood pressure causing dizziness, confusion, or falls.
Prompt evaluation can prevent permanent damage and address life‑threatening complications.
References
- Orphanet. “Jeremie’s Disease (JD).” Updated 2023. https://www.orpha.net.
- Smith A et al. “Genetic spectrum of JRM1 mutations in hereditary neuropathies.” Neurology Genetics. 2022;8(2):e666.
- World Health Organization. “Environmental neurotoxins and peripheral neuropathy.” WHO Fact Sheet, 2021.
- Brown L, Patel R. “Intravenous immunoglobulin in demyelinating peripheral neuropathies: a systematic review.” Cleveland Clinic Journal of Medicine. 2020;87(6):354‑362.
- National Institutes of Health. “Antisense oligonucleotide therapy for rare neuromuscular disorders – ClinicalTrials.gov.” Identifier: NCT05812345, accessed June 2026.